The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors
Open accessAbstract
The purpose of this study is to determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and intracerebral distribution of a recombinant toxin (TP-38) targeting the epidermal growth factor receptor in patients with recurrent malignant brain tumors using the intracerebral infusion technique of convection-enhanced delivery (CED). Twenty patients were enrolled and stratified for dose escalation by the presence of residual tumor from 25 to 100 ng/ml in a 40-ml infusion volume. In the last eight patients, coinfusion of (123)I-albumin was performed to monitor distribution within the brain. The MTD was not reached in this study. Dose escalation was stopped at 100 ng/ml due to inconsistent drug delivery as evidenced by imaging the coinfused (123)I-albumin. Two DLTs were seen, and both were neurologic. Median survival after TP-38 was 28 weeks (95% confidence interval, 26.5-102.8). Of 15 patients treated with residual disease, two (13.3%) demonstrated radiographic responses, including one patient with glioblastoma multiforme who had a nearly complete response and remains alive >260 weeks after therapy. Coinfusion of (123)I-albumin demonstrated that high concentrations of the infusate could be delivered >4 cm from the catheter tip. However, only 3 of 16 (19%) catheters produced intraparenchymal infusate distribution, while the majority leaked infusate into the cerebrospinal fluid spaces. Intracerebral CED of TP-38 was well tolerated and produced some durable radiographic responses at doses
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290
Cited by
Nanomaterial-based blood-brain-barrier (BBB) crossing strategies
Xie, J., Shen, Z., Anraku, Y., Kataoka, K., & Chen, X. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119491 · Cited by 604
Polymeric nanoparticles for drug delivery to the central nervous system
Patel, T., Zhou, J., Piepmeier, J. M., & Saltzman, W. M. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.12.006 · Cited by 565
Hadjipanayis, C. G., Machaidze, R., Kaluzova, M., Wang, L., Schuette, A. J., Chen, H., Wu, X., & Mao, H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1022 · Cited by 419
Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
S. Hersh, D., S. Wadajkar, A., B. Roberts, N., G. Perez, J., P. Connolly, N., Frenkel, V., A. Winkles, J., F. Woodworth, G., & J. Kim, A. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666151221150733 · Cited by 387
EGFR heterogeneity and implications for therapeutic intervention in glioblastoma
Eskilsson, E., Røsland, G. V., Solecki, G., Wang, Q., Harter, P. N., Graziani, G., Verhaak, R. G. W., Winkler, F., Bjerkvig, R., & Miletic, H. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox191 · Cited by 310
Metadata
- Authors
- Sampson, J. H., Akabani, G., Archer, G. E., Berger, M. S., Coleman, R. E., Friedman, A. H., Friedman, H. S., Greer, K., Herndon, J. E., Kunwar, S., McLendon, R. E., Paolino, A., Petry, N. A., Provenzale, J. M., Reardon, D. A., Wong, T. Z., Zalutsky, M. R., Pastan, I., & Bigner, D. D.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-06-01
- Volume
- 10
- Issue
- 3
- Pages
- 320-329
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2009063639
- Cited by
- 195
- References
- 2
- FWCI
- 9.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. https://app.cochat.ai/papers/10.1215/15228517-2008-012
- The paper
- Sampson, J. H., Akabani, G., Archer, G. E., Berger, M. S., Coleman, R. E., Friedman, A. H., Friedman, H. S., Greer, K., Herndon, J. E., Kunwar, S., McLendon, R. E., Paolino, A., Petry, N. A., Provenzale, J. M., Reardon, D. A., Wong, T. Z., Zalutsky, M. R., Pastan, I., & Bigner, D. D. (2008). Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro-Oncology. https://doi.org/10.1215/15228517-2008-012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.